Cargando…

The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II

AIMS: It is uncertain whether subclinical thyroid dysfunction is associated with cardiovascular disease (CVD) events and mortality in people with type 2 diabetes. The aim of this study was to determine whether undetected thyroid disease increases the risk of incident CVD and death in type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Chubb, S. A. Paul, Peters, Kirsten E., Bruce, David G., Davis, Wendy A., Davis, Timothy M. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581822/
https://www.ncbi.nlm.nih.gov/pubmed/36083409
http://dx.doi.org/10.1007/s00592-022-01969-x
_version_ 1784812713670606848
author Chubb, S. A. Paul
Peters, Kirsten E.
Bruce, David G.
Davis, Wendy A.
Davis, Timothy M. E.
author_facet Chubb, S. A. Paul
Peters, Kirsten E.
Bruce, David G.
Davis, Wendy A.
Davis, Timothy M. E.
author_sort Chubb, S. A. Paul
collection PubMed
description AIMS: It is uncertain whether subclinical thyroid dysfunction is associated with cardiovascular disease (CVD) events and mortality in people with type 2 diabetes. The aim of this study was to determine whether undetected thyroid disease increases the risk of incident CVD and death in type 2 diabetes. METHODS: One thousand two hundred fifty participants with type 2 diabetes (mean age 65.3 years, 56.5% males, median diabetes duration 8.0 years) without known thyroid disease and not taking medications known to affect thyroid function were categorised, based on baseline serum free thyroxine (FT4) and thyrotropin (TSH) concentrations, as euthyroid, overt hypothyroid (increased TSH, low FT4), subclinical hypothyroid (increased TSH, normal FT4), overt thyrotoxic (decreased TSH, raised FT4) or subclinical thyrotoxic (decreased TSH, normal FT4). Incident myocardial infarction, incident stroke, all-cause and cardiovascular mortality were ascertained during a mean 6.2–6.7 years of follow-up. RESULTS: Most participants with newly-detected thyroid dysfunction had subclinical hypothyroidism (77.2%) while overt/subclinical thyrotoxicosis was infrequent. Compared to participants with TSH 0.34–2.9 mU/L, those with TSH > 5.1 mU/L were not at increased risk of incident myocardial infarction (adjusted hazard ratio (95% confidence limits) 1.77 (0.71, 2.87)), incident stroke (1.66 (0.58, 4.78)), all-cause mortality (0.78 (0.44, 1.37)) or cardiovascular mortality (1.16 (0.38, 3.58)). Independent baseline associates of subclinical hypothyroidism included estimated glomerular filtration rate and systolic blood pressure. CONCLUSIONS: Subclinical hypothyroidism was not independently associated with CVD events or mortality in community-dwelling people with type 2 diabetes despite its associations with CVD risk factors, questioning strategies to identify and/or treat mild thyroid dysfunction outside usual care. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00592-022-01969-x.
format Online
Article
Text
id pubmed-9581822
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-95818222022-10-21 The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II Chubb, S. A. Paul Peters, Kirsten E. Bruce, David G. Davis, Wendy A. Davis, Timothy M. E. Acta Diabetol Original Article AIMS: It is uncertain whether subclinical thyroid dysfunction is associated with cardiovascular disease (CVD) events and mortality in people with type 2 diabetes. The aim of this study was to determine whether undetected thyroid disease increases the risk of incident CVD and death in type 2 diabetes. METHODS: One thousand two hundred fifty participants with type 2 diabetes (mean age 65.3 years, 56.5% males, median diabetes duration 8.0 years) without known thyroid disease and not taking medications known to affect thyroid function were categorised, based on baseline serum free thyroxine (FT4) and thyrotropin (TSH) concentrations, as euthyroid, overt hypothyroid (increased TSH, low FT4), subclinical hypothyroid (increased TSH, normal FT4), overt thyrotoxic (decreased TSH, raised FT4) or subclinical thyrotoxic (decreased TSH, normal FT4). Incident myocardial infarction, incident stroke, all-cause and cardiovascular mortality were ascertained during a mean 6.2–6.7 years of follow-up. RESULTS: Most participants with newly-detected thyroid dysfunction had subclinical hypothyroidism (77.2%) while overt/subclinical thyrotoxicosis was infrequent. Compared to participants with TSH 0.34–2.9 mU/L, those with TSH > 5.1 mU/L were not at increased risk of incident myocardial infarction (adjusted hazard ratio (95% confidence limits) 1.77 (0.71, 2.87)), incident stroke (1.66 (0.58, 4.78)), all-cause mortality (0.78 (0.44, 1.37)) or cardiovascular mortality (1.16 (0.38, 3.58)). Independent baseline associates of subclinical hypothyroidism included estimated glomerular filtration rate and systolic blood pressure. CONCLUSIONS: Subclinical hypothyroidism was not independently associated with CVD events or mortality in community-dwelling people with type 2 diabetes despite its associations with CVD risk factors, questioning strategies to identify and/or treat mild thyroid dysfunction outside usual care. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00592-022-01969-x. Springer Milan 2022-09-09 2022 /pmc/articles/PMC9581822/ /pubmed/36083409 http://dx.doi.org/10.1007/s00592-022-01969-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Chubb, S. A. Paul
Peters, Kirsten E.
Bruce, David G.
Davis, Wendy A.
Davis, Timothy M. E.
The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II
title The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II
title_full The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II
title_fullStr The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II
title_full_unstemmed The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II
title_short The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase II
title_sort relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: the fremantle diabetes study phase ii
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581822/
https://www.ncbi.nlm.nih.gov/pubmed/36083409
http://dx.doi.org/10.1007/s00592-022-01969-x
work_keys_str_mv AT chubbsapaul therelationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii
AT peterskirstene therelationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii
AT brucedavidg therelationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii
AT daviswendya therelationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii
AT davistimothyme therelationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii
AT chubbsapaul relationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii
AT peterskirstene relationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii
AT brucedavidg relationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii
AT daviswendya relationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii
AT davistimothyme relationshipbetweenthyroiddysfunctioncardiovascularmorbidityandmortalityintype2diabetesthefremantlediabetesstudyphaseii